ARCHIVES

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

This article is from The Cancer Letter archive.

Vol. 34 No. 36 | October 3, 2008

Download PDF Visit The Full Archive

Related Articles

Public Participation Hearings Develop Gals for Reducing Cancer Mortality

February 17, 1989

Amgen Agrees to Settle Aranesp Marketing Lawsuit, Reserves $780 Million For Settlement

October 28, 2011

DCE Reorganization Planned To Stem Departures, Stabilize

March 24, 1995

Shared Decisionmaking Called For In PSA Screening For Ages 55-69

May 31, 2013

Conversation with The Cancer Letter: Scott Soefje: “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”

October 3, 2014

Clinical Trials: NCI Removes Brooklyn Site From PLCO Trials

October 24, 1997